NO905255L - Fremgangsmaate for fremstilling av heterocyklisk substituerte acylaminotiazoler. - Google Patents

Fremgangsmaate for fremstilling av heterocyklisk substituerte acylaminotiazoler.

Info

Publication number
NO905255L
NO905255L NO90905255A NO905255A NO905255L NO 905255 L NO905255 L NO 905255L NO 90905255 A NO90905255 A NO 90905255A NO 905255 A NO905255 A NO 905255A NO 905255 L NO905255 L NO 905255L
Authority
NO
Norway
Prior art keywords
acylaminotiazoles
procedure
preparation
heterocyclic substituted
heterocyclic
Prior art date
Application number
NO90905255A
Other languages
English (en)
Other versions
NO179584B (no
NO905255D0 (no
NO179584C (no
Inventor
Jean-Pierre Bras
Daniel Frehel
Danielle Gully
Gerard Valette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO905255(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8916122A external-priority patent/FR2655344B1/fr
Priority claimed from FR9005669A external-priority patent/FR2661677B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO905255D0 publication Critical patent/NO905255D0/no
Publication of NO905255L publication Critical patent/NO905255L/no
Publication of NO179584B publication Critical patent/NO179584B/no
Publication of NO179584C publication Critical patent/NO179584C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
NO905255A 1989-12-06 1990-12-05 Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler NO179584C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8916122A FR2655344B1 (fr) 1989-12-06 1989-12-06 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR9005669A FR2661677B1 (fr) 1990-05-04 1990-05-04 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.

Publications (4)

Publication Number Publication Date
NO905255D0 NO905255D0 (no) 1990-12-05
NO905255L true NO905255L (no) 1991-06-07
NO179584B NO179584B (no) 1996-07-29
NO179584C NO179584C (no) 1996-11-06

Family

ID=26227714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO905255A NO179584C (no) 1989-12-06 1990-12-05 Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler

Country Status (19)

Country Link
US (2) US5189049A (no)
EP (1) EP0432040B2 (no)
JP (2) JP2760903B2 (no)
KR (1) KR0147281B1 (no)
AR (1) AR248138A1 (no)
AT (1) ATE109145T1 (no)
AU (1) AU628696B2 (no)
CA (1) CA2031463C (no)
DE (1) DE69011059T3 (no)
DK (1) DK0432040T3 (no)
ES (1) ES2057490T5 (no)
FI (1) FI94249C (no)
GR (1) GR3025940T3 (no)
HU (2) HU218276B (no)
IE (1) IE68593B1 (no)
IL (1) IL96577A (no)
LV (1) LV5802B4 (no)
MX (1) MX9203027A (no)
NO (1) NO179584C (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2768737B1 (fr) * 1997-09-19 2000-05-19 Sanofi Sa Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
UA66810C2 (uk) * 1997-10-27 2004-06-15 Агорон Фармацевтикалз Інк. Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ
FR2781227B1 (fr) 1998-07-20 2002-02-22 Sanofi Sa Procede pour la preparation du sel potassique du lintitript
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
DK1183245T3 (da) 1999-04-22 2007-09-24 Lundbeck & Co As H Selektive NPY(Y5)-antagonister
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US7732484B2 (en) * 2000-08-01 2010-06-08 University Of Virginia Patent Foundation Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis
ES2315350T3 (es) * 2001-01-12 2009-04-01 Waratah Pharmaceuticals Inc. Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
US7169931B2 (en) * 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1583530A4 (en) * 2002-01-16 2008-07-23 Univ Virginia 2-AMINOTHIAZOLE ALLOSTERIC AMPLIFIERS OF A1 ADENOSINE RECEPTORS
US7638536B2 (en) * 2002-01-18 2009-12-29 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
NZ552650A (en) * 2004-08-05 2010-09-30 Hoffmann La Roche Substituted N-acyl-2-aminothiazoles
RU2007109073A (ru) * 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
JP2009514941A (ja) * 2005-11-08 2009-04-09 アステラス製薬株式会社 血小板減少症を治療する化合物および方法
RU2008128453A (ru) * 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
WO2008021283A2 (en) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
US8138185B2 (en) 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
EP2464352A1 (en) * 2009-08-14 2012-06-20 Eisai Inc. Use of e5501 for stimulating platelet production
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
ES2634628T3 (es) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
EP3016951B1 (en) 2013-07-02 2017-05-31 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN109111427B (zh) * 2017-06-22 2023-06-02 中国科学院广州生物医药与健康研究院 一种吲哚类化合物及其应用
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN116194442A (zh) 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340092A2 (fr) * 1976-02-09 1977-09-02 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
AT367871B (de) * 1980-05-16 1982-08-10 Hoerbiger Ventilwerke Ag Anordnung zur selbsttaetigen druckentlastung von verdichtern
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
FR2566405B1 (fr) * 1984-06-25 1986-09-26 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
ATE67185T1 (de) * 1985-07-09 1991-09-15 Pfizer Substituierte oxindol-3-carboxamine als entzuendungshemmendes und schmerzstillendes mittel.
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4971978A (en) * 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
US4992437A (en) * 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
IL96577A0 (en) 1991-09-16
JPH03279374A (ja) 1991-12-10
IE904310A1 (en) 1991-06-19
JPH10130147A (ja) 1998-05-19
HK1002030A1 (en) 1998-07-24
HU211866A9 (en) 1995-12-28
LV5802A4 (lv) 1997-02-20
EP0432040B1 (fr) 1994-07-27
MX9203027A (es) 1992-07-01
NO179584B (no) 1996-07-29
HUT59400A (en) 1992-05-28
JP2760903B2 (ja) 1998-06-04
DE69011059T3 (de) 1998-04-09
FI94249C (fi) 1995-08-10
JP3035253B2 (ja) 2000-04-24
NO905255D0 (no) 1990-12-05
HU218276B (en) 2000-07-28
IE68593B1 (en) 1996-06-26
DE69011059T2 (de) 1995-03-02
KR0147281B1 (ko) 1998-08-17
CA2031463C (en) 2000-07-25
ES2057490T5 (es) 1998-03-16
CA2031463A1 (en) 1991-06-07
EP0432040A1 (fr) 1991-06-12
AR248138A1 (es) 1995-06-30
HU908075D0 (en) 1991-06-28
GR3025940T3 (en) 1998-04-30
FI905941A7 (fi) 1991-06-07
AU628696B2 (en) 1992-09-17
EP0432040B2 (fr) 1997-12-17
FI94249B (fi) 1995-04-28
DK0432040T3 (da) 1994-10-31
AU6777990A (en) 1991-06-20
LV5802B4 (lv) 1997-08-20
DE69011059D1 (de) 1994-09-01
IL96577A (en) 1994-06-24
KR910011814A (ko) 1991-08-07
USRE37094E1 (en) 2001-03-13
ATE109145T1 (de) 1994-08-15
ES2057490T3 (es) 1994-10-16
NO179584C (no) 1996-11-06
FI905941A0 (fi) 1990-12-03
US5189049A (en) 1993-02-23

Similar Documents

Publication Publication Date Title
NO905255D0 (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte acylaminotiazoler.
NO904987L (no) Fremgangsmaate for fremstilling av indolderivater.
NO900830D0 (no) Fremgangsmaate for fremstilling av piperidinforbindelser.
NO912411D0 (no) Fremgangsmaate for fremstilling av bicykliske heterocykliske forbindelser.
NO905008D0 (no) Fremgangsmaate for fremstilling av heterocykliske forbindelser.
NO902003L (no) Fremgangsmaate for fremstilling av n-heteroaryl-4-quinolinaminer.
NO901554L (no) Fremgangsmaate for fremstilling av dinatrium-cefodizim.
NO904285D0 (no) Fremgangsmaate for fremstilling av substituerte karboksytetrahydroisokinoliner.
NO903431D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO903275D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO903043D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO905377L (no) Fremgangsmaate for fremstilling av glycerolderivater.
NO905444L (no) Fremgangsmaate til fremstilling av oksazolderivater.
NO903207D0 (no) Fremgangsmaate for fremstilling av halogenaminoaromatiske derivater.
NO901690D0 (no) Fremgangsmaate til fremstilling av substituerte azetidinylisotiazolpyridon-derivater.
NO902762D0 (no) Fremgangsmaate for fremstilling av 5-fenyl-2-furan derivater.
NO901067L (no) Fremgangsmaate for fremstilling av tiofener.
NO900969L (no) Fremgangsmaate for fremstilling av n-allymetatrifluormetylanilin.
NO903666D0 (no) Fremgangsmaate for fremstilling av pyrrolokinolinforbindelser.
NO904060L (no) Fremgangsmaate for fremstilling av substituerte dibenzofuraner.
NO904535D0 (no) Fremgangsmaate for fremstilling av fenoxy-heterocykliske forbindelser.
NO900381D0 (no) Fremgangsmaate for fremstilling av nafthalenderivater.
NO905047D0 (no) Fremgangsmaate for fremstilling av selenofenderivater.
NO904070L (no) Fremgangsmaate for fremstilling av alkanfenoner.
NO904362D0 (no) Fremgangsmaate for fremstilling av kromanderivater.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JUNE 2003